Outcome of Board Meeting dated 14/02/2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Yash Chemex's board approved unaudited Q3 FY26 (quarter ended Dec 31, 2025) and nine-month standalone and consolidated financial results. On a standalone basis, nine-month revenue from operations rose to Rs. 5,931.67 lakhs from Rs. 4,012.36 lakhs (up ~47.8% YoY), while net profit was nearly flat at Rs. 127.74 lakhs (vs Rs. 127.99 lakhs). On a consolidated basis (includes subsidiary Yasons Chemex Care Ltd), nine-month revenue jumped to Rs. 10,305.44 lakhs (up ~57.7% YoY) and net profit rose to Rs. 291.52 lakhs from Rs. 239.42 lakhs (~21.8% growth). For the quarter alone, consolidated PAT surged sharply to Rs. 114.35 lakhs from just Rs. 5.78 lakhs a year ago. The auditor issued an unmodified limited review opinion. The board also appointed two new Independent Directors (Mr. Dhanik Mehta and Mr. Bhaveshkumar Shah) for 5-year terms and approved a postal ballot for shareholder approval.
Strong top-line growth driven mainly by subsidiary consolidation, with a notable jump in quarterly consolidated profit. Standalone profitability remained muted, indicating margin pressure at the parent level. Board strengthening with two new independent directors is governance-positive but unlikely to move the stock on its own.